Suran, MelissaMelissaSuranHswen, YulinYulinHswenNelson, AlondraAlondraNelsonBibbins-Domingo, KirstenKirstenBibbins-Domingo2024-01-222024-01-222024-01Suran M, Hswen Y. How Do Policymakers Regulate AI and Accommodate Innovation in Research and Medicine? JAMA. 2024;331(3):185–187. doi:10.1001/jama.2023.22625https://hdl.handle.net/20.500.12111/8179This conversation is part of a series of interviews in which JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD,MD, MAS, and expert guests explore issues surrounding the rapidly evolving intersection of artificial intelligence (AI) and medicine.What are the most recent advancements in establishing AI safeguards for clinical practice? In whatway does AI intersect with democracy and its preservation? And how are the frameworks for regulating AI progressing and aligning across the US, UK, and EU?As the technology advances at lightning speed, such questions surrounding AI become more critical. Alondra Nelson, PhD, is focusing on effective guardrails that protect society from issues like data insecurity—but also encourage innovation in the laboratory and clinic. Nelson is the Harold F. Linder Professor at the Institute for Advanced Study in Princeton, New Jersey, where she studies the effects of scientific and technological advances on health and society. In 2023, she was included in TIME magazine’s 100 most influential people in AI. JAMA Editor in Chief Kirsten-Bibbins Domingo, PhD, MD, MAS, recently spoke with Nelson, who also served as deputy assistant to US President Joe Biden and was acting director of the White House Office of Science and Technology Policy (OSTP). The following interview has been edited for clarity and length. The video of this interview can be seen here: https://jamanetwork.com/learning/video-player/18841089en-USRegulatory AgenciesHealth PolicyArtificial IntelligenceOtherdoi:10.1001/jama.2023.22625